Show simple item record

dc.contributor.authorClarke, NW
dc.contributor.authorAli, A
dc.contributor.authorIngleby, FC
dc.contributor.authorHoyle, A
dc.contributor.authorAmos, CL
dc.contributor.authorAttard, G
dc.contributor.authorBrawley, CD
dc.contributor.authorCalvert, J
dc.contributor.authorChowdhury, S
dc.contributor.authorCook, A
dc.contributor.authorCross, W
dc.contributor.authorDearnaley, DP
dc.contributor.authorDouis, H
dc.contributor.authorGilbert, D
dc.contributor.authorGillessen, S
dc.contributor.authorJones, RJ
dc.contributor.authorLangley, RE
dc.contributor.authorMacNair, A
dc.contributor.authorMalik, Z
dc.contributor.authorMason, MD
dc.contributor.authorMatheson, D
dc.contributor.authorMillman, R
dc.contributor.authorParker, CC
dc.contributor.authorRitchie, AWS
dc.contributor.authorRush, H
dc.contributor.authorRussell, JM
dc.contributor.authorBrown, J
dc.contributor.authorBeesley, S
dc.contributor.authorBirtle, A
dc.contributor.authorCapaldi, L
dc.contributor.authorGale, J
dc.contributor.authorGibbs, S
dc.contributor.authorLydon, A
dc.contributor.authorNikapota, A
dc.contributor.authorOmlin, A
dc.contributor.authorO'Sullivan, JM
dc.contributor.authorParikh, O
dc.contributor.authorProtheroe, A
dc.contributor.authorRudman, S
dc.contributor.authorSrihari, NN
dc.contributor.authorSimms, M
dc.contributor.authorTanguay, JS
dc.contributor.authorTolan, S
dc.contributor.authorWagstaff, J
dc.contributor.authorWallace, J
dc.contributor.authorWylie, J
dc.contributor.authorZarkar, A
dc.contributor.authorSydes, MR
dc.contributor.authorParmar, MKB
dc.contributor.authorJames, ND
dc.date.accessioned2019-12-06T15:05:41Z
dc.date.issued2019-12
dc.identifier.citationAnnals of oncology : official journal of the European Society for Medical Oncology, 2019, 30 (12), pp. 1992 - 2003
dc.identifier.issn0923-7534
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/3446
dc.identifier.eissn1569-8041
dc.identifier.doi10.1093/annonc/mdz396
dc.description.abstractBackground STAMPEDE has previously reported that the use of upfront docetaxel improved overall survival (OS) for metastatic hormone naïve prostate cancer patients starting long-term androgen deprivation therapy. We report on long-term outcomes stratified by metastatic burden for M1 patients.Methods We randomly allocated patients in 2 : 1 ratio to standard-of-care (SOC; control group) or SOC + docetaxel. Metastatic disease burden was categorised using retrospectively-collected baseline staging scans where available. Analysis used Cox regression models, adjusted for stratification factors, with emphasis on restricted mean survival time where hazards were non-proportional.Results Between 05 October 2005 and 31 March 2013, 1086 M1 patients were randomised to receive SOC (n = 724) or SOC + docetaxel (n = 362). Metastatic burden was assessable for 830/1086 (76%) patients; 362 (44%) had low and 468 (56%) high metastatic burden. Median follow-up was 78.2 months. There were 494 deaths on SOC (41% more than the previous report). There was good evidence of benefit of docetaxel over SOC on OS (HR = 0.81, 95% CI 0.69-0.95, P = 0.009) with no evidence of heterogeneity of docetaxel effect between metastatic burden sub-groups (interaction P = 0.827). Analysis of other outcomes found evidence of benefit for docetaxel over SOC in failure-free survival (HR = 0.66, 95% CI 0.57-0.76, P < 0.001) and progression-free survival (HR = 0.69, 95% CI 0.59-0.81, P < 0.001) with no evidence of heterogeneity of docetaxel effect between metastatic burden sub-groups (interaction P > 0.5 in each case). There was no evidence that docetaxel resulted in late toxicity compared with SOC: after 1 year, G3-5 toxicity was reported for 28% SOC and 27% docetaxel (in patients still on follow-up at 1 year without prior progression).Conclusions The clinically significant benefit in survival for upfront docetaxel persists at longer follow-up, with no evidence that benefit differed by metastatic burden. We advocate that upfront docetaxel is considered for metastatic hormone naïve prostate cancer patients regardless of metastatic burden.
dc.formatPrint
dc.format.extent1992 - 2003
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.subjectHumans
dc.subjectProstatic Neoplasms
dc.subjectNeoplasm Metastasis
dc.subjectDisease Progression
dc.subjectAndrogen Antagonists
dc.subjectAntineoplastic Combined Chemotherapy Protocols
dc.subjectProportional Hazards Models
dc.subjectRetrospective Studies
dc.subjectAged
dc.subjectMiddle Aged
dc.subjectMale
dc.subjectDocetaxel
dc.subjectProgression-Free Survival
dc.titleAddition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial.
dc.typeJournal Article
rioxxterms.versionofrecord10.1093/annonc/mdz396
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2019-12
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfAnnals of oncology : official journal of the European Society for Medical Oncology
pubs.issue12
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams/Clinical Academic Radiotherapy (Dearnaley)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Treatment Resistance
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Prostate and Bladder Cancer Research
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams/Clinical Academic Radiotherapy (Dearnaley)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Treatment Resistance
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Prostate and Bladder Cancer Research
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished
pubs.volume30
pubs.embargo.termsNot known
icr.researchteamClinical Academic Radiotherapy (Dearnaley)en_US
icr.researchteamTreatment Resistanceen_US
icr.researchteamProstate and Bladder Cancer Researchen_US
dc.contributor.icrauthorParker, Chrisen
dc.contributor.icrauthorDearnaley, Daviden
dc.contributor.icrauthorAttard, Gerhardten
dc.contributor.icrauthorJames, Nicholasen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0